The benzylic alcohols 1-and 2-hydroxy-3-methylcholanthrene (OH-MC) are major primary metabolites of the carcinogen 3-methylcholanthrene (MC). We investigated them for mutagenicity in TA1538-derived Salmonella typhimurium strains expressing mammalian sulphotransferases (SULTs). 1-OH-MC was efficiently activated by human (h) SULT1B1 (2400 revertants/nmol), weakly activated by hSULT1C3 and hSULT2A1 (2-9 revertants/nmol), but not activated by the other hSULTs studied (1A2, 1A3, 1C2 and 1E1). Mouse, rat and dog SULT1B1 activated 1-OH-MC (8-100 revertants/nmol) with much lower efficiency than their human orthologue. The other isomer, 2-OH-MC, was activated to a potent mutagen by hSULT1A1 (4000-5400 revertants/nmol), weakly activated by hSULT1A2 or hSULT2A1 (1-12 revertants/nmol), but not activated by the other hSULTs. In contrast to their human orthologue, mouse, rat and dog SULT1A1 did not appreciably activate 2-OH-MC (<1 to 6 revertants/nmol), either. Instead, mouse and rat SULT1B1, unlike their human and canine orthologues, demonstrated some activation of 2-OH-MC (15-100 revertants/nmol). Docking analyses indicated that 1-and 2-OH-MC might bind to the active site of hSULT1A1 and hSULT1B1, but only for (S)-2-OH-MC/hSULT1A1 and (R)-1-OH-MC/hSULT1B1 with an orientation suitable for catalysis. Indeed, 1-and 2-OH-MC were potent inhibitors of the hSULT1A1-mediated sulphation of acetaminophen [concentration inhibiting the enzyme activity by 50% (IC 50 ) 15 and 13 nM, respectively]. This inhibition was weak with mouse, rat and dog SULT1A1 (IC 50 ≥ 4 µM). Inhibition of the SULT1B1 enzymes was moderate, strongest for 1-OH-MC/hSULT1B1. In conclusion, this study provides examples for high selectivity of bioactivation of promutagens by an individual form of human SULT and for pronounced differences in activation capacity between orthologous SULTs from different mammalian species. These characteristics make the detection and evaluation of such mutagens extremely difficult, in particular as the critical form may even differ for positional isomers, such as 1-and 2-OH-MC.
Introduction
3-Methylcholanthrene (MC) is an alkylated polycyclic aromatic hydrocarbon (PAH) formed from the pyrolysis of deoxycholic acid (1) . As early as 1935, it was observed that MC induces tumours faster than other PAHs tested previously, such as the purely aromatic hydrocarbon benzo [a] pyrene detected in coal tar (2, 3) . Although no significant exposure of humans to MC was observed, its high carcinogenic activity promoted further research on this PAH. Subsequently, MC was the first compound detected to induce xenobiotic-metabolizing enzymes (4, 5) . It is still widely used for the activation of the arylhydrocarbon receptor in animal and cell culture models.
Hydroxylation at the 1-and 2-positions are the major primary biotransformation reactions of MC (6, 7) . MC forms many different DNA adducts in mouse tissues, as demonstrated by the 32 P-post-labelling method (8) . Its major adduct spots were also detected after topical administration of the metabolites 1-hydroxy-3-methylcholanthrene (1-OH-MC) and 2-hydroxy-3-methylcholanthrene (2-OH-MC; structural formulas are shown in Figure 1 ) to mouse skin (8) . Sims (9) injected MC, 1-OH-MC, 2-OH-MC and the corresponding keto derivatives (which are readily formed from the alcohols by autoxidation) subcutaneously into mice. All compounds were strongly carcinogenic. Cavalieri et al. (10) administered the same compounds chronically on mouse skin. MC, 2-OH-MC and 2-keto-MC were more potent inducers of skin tumours (often with metastases into the lungs) than 1-OH-MC, whereas 1-keto-MC provided a negative result. A similar ranking was observed by Levin et al. (11) , who studied the tumour-initiating activity in skin of adult mice and the formation of pulmonary and hepatic tumours in the newborn mouse model. Additionally, they tested 1-OH-MC-9,10-dihydrodiol. This compound was more potent than MC in the newborn mice, but less active than the parent hydrocarbon in the skin model. The authors conclude that a bay-region dihydrodiolepoxide formed via 1-OH-MC and 1-OH-MC-9,10-dihydrodiol is a potential ultimate carcinogen of MC. However, based on these data, it is likely that further metabolites substantially contribute to the carcinogenicity of MC. 1-and 2-OH-MC are benzylic alcohols and thus might be converted to reactive esters by sulphotransferases (SULTs) (12, 13) . Indeed, Jeong et al. (14) observed that chemically synthesised 1-sulphooxy-MC is mutagenic in bacteria and forms DNA adducts. Flesher et al. (15) found that 1-sulphooxy-MC is a more potent inducer of sarcomas than 1-OH-MC after repeated subcutaneous administration to rats. To the best of our knowledge, it has not yet been studied whether 1-and 2-OH-MC are substrates for any SULTs, apart from our previous short note that 1-and 2-OH-MC were activated to weak mutagens in Salmonella typhimurium TA1538 upon expression of human SULT2A1. In the meantime, we have expressed all human and various other mammalian SULT forms in S.typhimurium. We have resumed the investigation of 1-and 2-OH-MC. The results are impressive as each isomer was activated with high selectivity by an individual, but different, human SULT form and as orthologous enzymes from different mammalian species substantially differed in their activation capacity for these compounds.
Materials and methods
Chemicals 1-and 2-OH-MC were obtained from the NCI Chemical Carcinogen Reference Standards Repository (Kansas City, Missouri, USA). 1-Hydroxymethylpyrene (1-HMP) was purchased from Sigma-Aldrich (Taufkirchen, Germany). 3′-Phosphoadenosine-5′-phosphosulphate (PAPS) was prepared using recombinant human PAPS synthetase 1, expressed in Escherichia coli and purified by preparative anion exchange high-performance liquid chromatography (HPLC). Its purity was ≥99%, as determined by HPLC with ultraviolet detection.
Bacterial strains
Human SULTs (reference-type sequences) were expressed in S.typhimurium TA1538 using the pKK233-2 vector, as described previously (16, 17) . To be consistent with our previous publications, we maintained the original designation of SULTs. This is relevant for SULT1C1 and SULT1C2, which have been renamed to SULT1C2 and SULT1C4, respectively, by Blanchard et al. (18) .
Canine SULT1A1 and SULT1B1 were cloned and inserted into the vectors pK233-3 and pK233-2, respectively, as described previously (19, 20) . Rodent SULTs were expressed by inserting the open reading frame of the following complementary DNA sequences into the pKK233-2 vector: mouse SULT1A1 (GenBank accession number: L02331), mouse SULT1B1 (U92076), rat SULT1A1 (X52883) and rat SULT1B1 (U38419).
The names of the strains are composed of the name of the recipient strain (TA1538 in this study) and that of the expressed SULT form (with the prefixes h, m, r and d for human, mouse, rat and dog forms, respectively).
Detection of SULT1A1 and SULT1B1 proteins in S.typhimurium strains
Cytosolic fractions from bacteria were prepared as described previously (16, 17) . Total protein content was determined using the bicinchoninic acid assay (Thermo Fisher Scientific, Bonn, Germany) in microtitre plates according to the manufacturer's recommendation with bovine serum albumin as a standard. Cytosolic fractions were electrophoretically separated on 11% sodium dodecylsulphatepolyacrylamide gels, which were subsequently either stained with Coomassie brilliant blue or electrotransferred to Hybond ECL membranes (GE Healthcare, Braunschweig, Germany) for immunodetection. Antisera raised against human SULTs were initially used for the immunoanalysis. However, both mouse forms were hardly detected by these antisera raised against their human orthologues. Therefore, we raised new antisera in rabbits against inclusion bodies of mSULT1A1 and mSULT1B1, as described previously for other SULT forms (16, 17) . All primary antisera were used in a dilution of 1:10 000. Secondary anti-rabbit or anti-sheep antibodies coupled with horseradish peroxidase were obtained from Sigma-Aldrich and used in a dilution of 1:2500. Enhanced chemiluminescence was employed to detect immunoreactive bands. They were visualised in an Image Quant LAS 4000 system (GE Healthcare). mSULT1A1, mSULT1B1 and rSULT1A1 inclusion bodies, loaded at varying levels on separate lanes, were used as standard for quantifying their levels in the recombinant strains. No inclusions bodies were available for dSULT1A1, dSULT1B1 and rSULT1B1 expressed in other new strains. In these cases, the immunoblots were only used for identifying the location of the SULTs on the gels. Quantification was attempted by comparing the intensity of the corresponding band in the Coomassie-stained gels using the Image Quant LAS 4000 system.
Mutagenicity testing
The bacteria were grown in Nutrient Broth No. 2 (Oxoid GmbH, Wesel, Germany) at 37°C with shaking for 8 h. Strain TA1538 was grown in the absence of antibiotics. Ampicillin (50 µg/ml) was added to the growth medium for the recombinant strains. The cultures were centrifuged, suspended in medium A (1.6 g/l Bacto Nutrient Broth and 5 g/l NaCl), adjusted turbidimetrically to a titre of 1-2 × 10 9 bacteria (colony-forming units)/ml and kept on ice. Shortly before use, they were centrifuged again and suspended at a 5-fold higher density in medium A. Mutagenicity was determined using a modified version of the liquid pre-incubation assay described by Maron and Ames (21) . The bacterial suspension (100 µl) and the test compound (in 10 µl dimethylsulphoxide) were added sequentially to a glass tube containing 500 µl of 100 mM MgSO 4 . After incubation for 60 min at 37°C, 2 ml of 45°C warm soft agar (5.5 mg/ml agar, 5.5 mg/ml NaCl, 50 µM biotin, 50 µM histidine, 50 µM tryptophan, 25 mM sodium phosphate buffer, pH 7.4) was added, and the mixture was poured onto a Petri dish containing 24 ml of minimal agar (15 mg/ml of agar in Vogel-Bonner E medium with 20 mg/ml of glucose). After incubation for 3 days in the dark, the colonies (his + revertants) were counted. Incubations were carried out in triplicate or quadruplicate, except for the negative controls (usually double number of plates). The result was evaluated as follows. It was classified as positive if the number of revertants (mean value at any dose level) was increased at least 3-fold above the number of spontaneous revertant colonies with a plausible dose-response relationship. It was also classified as positive if the increase was at least 2-fold and confirmed in repeated experiments. Specific mutagenicities (revertants per nmol) were calculated from the slope of the initial part of the dose-response curve of the positive results. For negative results, a conservative limit of detection is given by dividing the number of spontaneous revertants by the highest dose that could be adequately tested (no obvious toxicity).
Docking analyses
Molecular operating environment (MOE) served as the platform for all in silico compound fabrication, structure file manipulation and docking studies (22) , whereas PyMOL software assisted in the visualisation of results and generation of images. Both enantiomeric forms of 1-and 2-OH-MC were constructed in silico using the MOE builder function. Publicly available structures 2D06 and 3CKL served as the assumed architecture for hSULT1A1 and hSULT1B1, respectively (23, 24) . Each protein database file contains the atomic coordinates for the human SULT form in a closed conformation with 3′-phosphoadenosine-5′-phosphate (PAP) in the cofactor-binding site and the potential acceptor substrate bound in the adjacent active site. Only one structure is available in which a SULT is co-crystallised with the complete cofactor, PAPS. The orientation of the cofactor in this structure file (protein database ID: 1HY3) was used as the assumed coordination of PAPS when docked into a SULT enzyme (25) . Following spatial alignment of structures 2D06 and 1HY3, the PAP atoms from structure 2D06 and the protein atoms from structure 1HY3 were removed, resulting in the preservation of the SULT1A1/substrate complex and PAPS in an acceptable location within the enzyme that is nearly superimposable with the previously present PAP molecule. The entire system was protonated using MOE Protonate 3D with default parameters (26, 27) . The PAPS molecule was subjected to an energy minimisation function using the Amber12:EHT forcefield. MOE default settings were retained for all unspecified parameters. The same steps were employed to prepare the hSULT1B1 model. The resulting structures served as the final closed SULT models for all docking analyses.
Each enantiomer of 1-and 2-OH-MC was docked into each rigid enzyme model in the closed state. The potential docking site was defined by selecting all protein residues in proximity to co-crystallised substrates found in the original structures. Various ligand conformations were explored by allowing substrate bond rotation within acceptable boundaries. Triangle matcher method was used to place the conformers in the active site of the target receptor based on spatial fit and charge distribution (28, 29) . Optimal orientation was explored via a random manner. These conformers were ranked with the London dG scoring function and the 30 poses yielding the most suitable binding free energy (BFE) were retained for refinement by the Amber12:EHT forcefield (30) . These poses were then subjected to another scoring function (Affinity dG), from which a final 30 conformations were retained (31) . The resulting molecule orientations of each trial were evaluated for both binding affinity and catalytic potential according to specifications previously described (32) .
Determination of acetaminophen sulphation activity
The OH-MCs are substrates for some SULTs studied, as demonstrated by the positive mutagenicity results. The docking analyses suggested that they might bind to the active sites of SULTs in a non-productive manner in other cases. Both interactions should lead to inhibition of the conjugation of other substrates, most likely in a competitive manner. From previous unpublished work, we knew that acetaminophen is a substrate for hSULT1A1 and mSULT1A1 with K m values of nearly 200 µM. A relatively low substrate concentration (in the range or below the K m ) appeared appropriate for the main purpose of the experiments, the detection of inhibition. In an initial experiment, we verified that the remaining SULT1A1 and SULT1B1 also conjugate acetaminophen (used at a concentration of 200 µM) and determined protein levels with linear formation of acetaminophen sulphate (total cytosolic protein: 5 µg of TA1538-hSULT1A1, 50 µg of TA1538-rSULT1A1 and 10 µg of the other strains). The incubation mixture (100 µl in an Eppendorf vial) contained this amount of cytosolic fraction, sodium phosphate buffer (50 mM, pH 7.5), the co-substrate PAPS (50 µM), acetaminophen (200 µM), OH-MCs (0-40 µM) and dimethylsulphoxide (2 µl, used as the solvent for adding OH-MCs). This mix, but initially without substrate, inhibitor and their solvents, was incubated at 37°C for 2 min. Then, the OH-MC (or its solvent only) was added. After further pre-incubation at 37°C for 2 min, the reaction was started by adding acetaminophen (in 5 µl of water). After incubation at 37°C for 30 min, the vial was transferred to a block heated at 95°C for 2 min to denature the protein. Denatured protein was precipitated by incubation on ice for 10 min followed by centrifugation at 16 000 × g for 10 min. An 80-µl aliquot of the supernatant was transferred into an HPLC glass vial, which was sealed with a septum. Acetaminophen sulphate and acetaminophen were separated by HPLC (Dionex, Idstein, Germany) using a NovaPak C18 column (Waters), 150 × 3.9 mm, at 30°C isocratically with 0.1 M KH 2 PO 4 containing (v/v) 0.1% acetic acid, 0.75% isopropanol and 4% methanol at a flow rate of 0.7 ml/min. The compounds were detected at 242 nm using an ultraviolet diode array detector. Acetaminophen sulphate was quantified with external calibration with standards ranging from 0.1 to 10 µM. Samples were determined in triplicate.
Results

SULT protein levels in the recombinant strains
The levels of the human SULT proteins in the cytosolic fraction of recombinant strains (Table I) were estimated previously (16, 17) . Expression of the SULT proteins in the newly constructed strains was verified by immunoblotting ( Figure 2 ). Antibodies against hSULT1A1 also recognised the canine and rat orthologues, but not the enzyme of the mouse (Figure 2A ). Therefore, we raised an antiserum against mSULT1A1 inclusion bodies. It detected mouse, rat and dog SULT1A1, but not the human orthologue ( Figure 2B ). Likewise, antibodies raised against hSULT1B1 did not recognise all orthologous SULT1B1 proteins ( Figure 2C ). However, the forms missed by anti-hSULT1B1 antiserum were detected by an antiserum raised against mSULT1B1 inclusion bodies ( Figure 2D) . Levels of mSULT1A1, rSULT1A1 and mSULT1B1 were estimated from immunoblots using nearly homogeneous inclusion bodies as standards. Levels of rSULT1A1 were lower than those of all other SULTs studied (Table I) . This was also reflected in lower acetaminophen sulphation activity in cytosolic preparations from strain TA1538-rSULT1A1 compared to the strains expressing human, dog or mouse SULT1A1 (Table  II) . No inclusion bodies or purified enzymes were available for dSULT1A1, rSULT1B1 and dSULT1B1. Their levels were estimated from Coomassie-stained gels. The level of dSULT1A1 was difficult to estimate, as it co-migrated with an endogenous protein of S.typhimurium TA1538. However, acetaminophen sulphation activity in cytosolic preparations from strain TA1538-dSULT1A1 was similar to that observed with strain TA1538-hSULT1A1 (Table II) .
Mutagenicity of the SULT-dependent positive control 1-HMP 1-HMP was not mutagenic in the parental strain TA1538, but it was activated to a mutagen by all SULT forms used in this study. The results are summarised in Table I . Some doseresponse curves will be discussed later. The highest mutagenic activities were observed in strains expressing human SULT1E1 and human, mouse and canine SULT1A1. Five further human SULT forms (1C1, 2B1a, 2B1b, 4A1 and 6B1) were not used in this study. We expressed these forms in S.typhimurium, but none of them activated 1-HMP or any other potential positive control investigated (>20 compounds known to be activated by other SULT forms). Although cytosolic fractions of strains expressing SULT1C1, 2B1a and 2B1b demonstrated enzyme activity with reference substrates, SULT4A1 and 6B1 represent orphan forms without any known substrates. 1-and 2-OH-MC, available only in small quantities, were not studied with these little promising SULT forms.
Activation of 1-and 2-OH-MC by human SULTs
1-OH-MC was strongly mutagenic in strain TA1538-hSULT1B1 ( Figure 3A, solid circles) . Although the maximal increase in the number of revertants was moderate (nearly 4-fold), it occurred Estimated in this study from immunoblots using nearly homogeneous inclusion bodies as standards, as described for other SULT forms in (16) .
f Estimated in this study from Coomassie-stained gels as described for other SULT forms in (16) . dSULT1A1 co-migrated with endogenous proteins of S.typhimurium forming a relatively strong band. Therefore, a higher range had to be given for the estimated level of this form than for other SULTs.
at low doses, leading to high specific mutagenicity (2700, 2400 and 2100 revertants/nmol in three separate experiments). When the dose level was increased above 0.08 nmol per plate, 1-OH-MC became bacteriotoxic to strain TA1538-hSULT1B1, as indicated by a decrease in the number of colonies and dilution of the His − background lawn. 1-OH-MC was neither mutagenic nor cytotoxic to the parental strain TA1538 (Figures 3 and 4 , open circles) and in strains expressing human SULT1A1 ( Figure 4A , solid circles), 1A2, 1A3, 1C2 or 1E1. Modest activations were observed with human SULT1C3 and 2A1 (Table I) .
The positional isomer, 2-OH-MC, was strongly mutagenic in strains expressing human SULT1A1 ( Figure 4B, solid circles) . A 7-fold increase in the level of this enzyme (strain TA1538-hSULT1A1*1Y vs. TA1538-hSULT1A1) only led to a modest (1.3-fold) increase in the mutagenic activity of 2-OH-MC (Table I ), indicating that the substrate rather than the enzyme was primarily limiting for the activation. Slight mutagenic effects were observed with SULT1A2 and 2A1, but not with any other human SULT form studied (Table I) .
Activation of 1-HMP, 1-OH-MC and 2-OH-MC by SULT1A1 and SULT1B1
forms from different mammalian species 1-HMP produced nearly superimposable dose-mutagenicity curves in strains expressing either human, mouse or canine SULT1A1 ( Figure 4C ). Rat SULT1A1 also activated it, although higher substrate concentrations were required. On the contrary, only the human enzyme efficiently activated 2-OH-MC ( Figure 4B ). The number of revertants induced per nmol 2-OH-MC amounted to 4000, 6, <1 and <1 in strains TA1538-hSULT1A1, -dSULT1A1, -mSULT1A1 and -rSULT1A1, respectively. None of these SULT1A1 forms activated the positional isomer, 1-OH-MC ( Figure 4A ).
All SULT1B1 forms activated 1-HMP ( Figure 3C ), although less efficiently than the SULT1A1 enzymes. The initial part of the dose-mutagenicity curves for 1-HMP was similar in strains TA1538-hSULT1B1 and -dSULT1B1 leading to equal specific mutagenicities (90 revertants/nmol). However, the mutagenic effects levelled off rapidly with the human enzyme, but continued to increase over a wide dose range with the canine enzyme. This difference was confirmed in several repeat experiments with each strain. 1-HMP was less mutagenic by factors of 3.6 and 6, when rat and mouse SULT1B1, respectively, were expressed rather the corresponding human or canine enzymes. These differences were much larger with 1-OH-MC as the test substance. The mutagenic activities observed in the presence of human SULT1B1 exceeded those found in strains expressing the canine, rat and mouse orthologues by factors of 24, 53 and 300, respectively. Instead, mouse and rat SULT1B1, showing the weakest activation of 1-OH-MC and 1-HMP among the orthologues, activated the isomer, 2-OH-MC, unlike canine and human SULT1B1 ( Figure 3B ). The negative result of 2-OH-MC with human SULT1B1 may be debatable, as there was a dosedependent increase in the number of the revertant colonies in each of four repeat experiments conducted (one being shown in Figure 3B , solid circles), but the maximal increases above the negative control were only 1.5-, 1.7-, 1.7-and 2.0-fold, implying a negative result according to our criteria. In any case, a possible mutagenic activity was low (<1 revertant/nmol).
Docking analyses for hSULT1A1 and hSULT1B1
Crystal structures for both of these enzymes provide an avenue for investigating SULT/OH-MC interactions at the atomic level through in silico docking analyses (23-25). 1-and 2-OH-MC are chiral molecules used as their racemic mixtures in the mutagenicity experiments. The docking analyses were conducted with each individual enantiomer. Despite the altered location of the -OH along the otherwise identical chemical backbone, all four compounds docked in nearly superimposable fashions within the active site of hSULT1A1 ( Figure 5A ). We observed similar results with hSULT1B1 ( Figure 5B ). This clustered orientation was observed at a high frequency within the 30 docking trials for each ligand/enzyme pair, increasing our confidence that the clustering sites were the favoured orientation of the molecules within each respective active site. Also, no other docking orientation exhibited clusters or an impressive BFE. All clustered compounds exhibited exceptional free energy profiles, below −10.5 kJ, suggesting they are high-affinity ligands for the two SULT forms (Table  III) . The top recorded BFE values were only slightly variable within enzyme respective docking groups (Table III) . The docking study suggested that each compound would bind each enzyme form active site with a relatively high affinity regardless of the location of the -OH along the backbone of the molecule. It is important to differentiate between binding potential and catalytic potential when discussing enzyme/substrate pairs. Although all compounds docked into each enzyme with relatively high binding affinities, most were not oriented in a position to allow enzyme-mediated sulphation. The ability of the enzyme to catalyse the sulpho transfer to the potential substrate is governed largely by the location of the -OH moiety within the active site of the enzyme, namely its proximity and orientation with respect to the catalytic histidine residue (His109 in hSULT1B1 and His108 in SULT1A1). The most abundant and energetically favourable docking orientations of each compound were achieved when the molecule entered the pocket leading with its methyl group ( Figure 5A and B) . The planar nature of the OH-MC molecules was fairly conserved upon docking all compounds. This planar docking orientation divides the pocket into halves, leaving the catalytic histidine accessible to only one side of the compound, abolishing the potential for catalytic orientation of any OH-MC isomer presenting the -OH moiety on the opposing side of the molecule ( Figure 5C ). As expected, neither of the molecules fitting this description, (S)-1-OH-MC and (R)-2-OH-MC, docked in a catalytic orientation in either enzyme, providing argumentative grounds for enantio-selectivity by both enzymes (Table III) . Interestingly, (S)-2-OH-MC docked catalytically in the hSULT1A1 active site, but not in hSULT1B1 (Table III) . Complementary to this result, (R)-1-OH-MC docked into the hSULT1B1 active site in a catalytic orientation, whereas it failed to do so in hSULT1A1. Although compound clustering was observed within docking groups for each respective enzyme, the overall orientations of the molecules in the active sites of hSULT1A1 and hSULT1B1 were different with respect to one another. In hSULT1A1, the molecules were restricted to a shallow position in the active site, leaving only the most distal -OH location (position 2) accessible to the catalytic histidine ( Figure 5D ). The hSULT1B1 compounds docked nearly 2 Å deeper in the active site, accompanied by a 22° change in pitch of each molecule ( Figure 5D ). This orientation of the compound positions the proximal -OH location (position 1) in reach of the catalytic histidine while burying position 2 deep inside the pocket, preventing its interaction with His109. Also worth noting, the backside of the molecules was bent nearly 2 Å out of plane upon docking into hSULT1B1, likely contributing to an overall decrease in BFE of the molecules compared to those docked into hSULT1A1 ( Figure 5E and Table III) . Upon structural alignment of each enzyme paired with its respective catalytically oriented OH-MC, the location of the -OH moieties of the two OH-MC molecules is nearly identical with respect to the superimposable histidine residues ( Figure 5E ). Overall, these results provide a rationale for binding and selective sulphation of 1-and 2-OH-MC by hSULT1A1 and hSULT1B1.
Inhibition of acetaminophen sulphation by 1-and 2-OH-MC
The strong mutagenicity of racemic 1-OH-MC in strain TA1538-hSULT1B1 implies that at least one of its enantiomers is a substrate for hSULT1B1. The same is true for 2-OH-MC and hSULT1A1. The results of the docking analyses suggest that (S)-2-OH-MC and (R)-1-OH-MC, respectively, might be the substrates. Therefore, they should compete with the sulphation of other substrates by these enzymes.
Additionally, the docking results suggest that the complementary enantiomers and the positional isomers also bind to the active site, but in an unproductive manner, which would also result in enzyme inhibition. Therefore, we determined enzyme activities of the various SULT1A1 and SULT1B1 enzymes (used as cytosolic preparations of the recombinant strains) in the presence and absence of the OH-MCs. Acetaminophen was used as the substrate, as it is metabolised by all SULT forms studied, although at varying rates (Table II) .
By far the strongest inhibition was observed with hSULT1A1 (Table II) . Comparable inhibition of this enzyme was found with 2-OH-MC (substrate) and 1-OH-MC (no substrate). Their concentration inhibiting the enzyme activity by 50% (IC 50 ) values were nearly 13 and 15 nM, respectively, (Figure 6 ), which is <0.01% of the concentration of the substrate used (200 µM of acetaminophen). Thus, the OH-MCs bound to hSULT1A1 with exceptionally high affinity. Interestingly, the orthologous SULT1A1 enzymes from mouse, rat and dog were only moderately inhibited by the OH-MCs. Canine SULT1A1 was inhibited by 56% in the presence of 4 µM of 2-OH-MC. Thus, the IC 50 was slightly <4 µM. The other inhibitions of non-human SULT1A1 enzymes were even weaker. Therefore, we conclude that hSULT1A1 differs from the non-human SULT1A1 orthologues studied by a drastically increased affinity for both OH-MCs. This difference may explain the lack of bioactivation of 2-OH-MC by non-human SULT1A1 forms and the lack of bioactivation of 1-OH-MC by dSULT1A1 and rSULT1A1. The observation that 1-OH-MC was activated to a mutagen by mSULT1A1 (with intermediate efficiency), but inhibited the sulphation of acetaminophen by this enzyme only moderately, suggests that it is a low-affinity substrate.
Both OH-MCs inhibited all SULT1B1 enzymes (Table II) . The strongest inhibition in this set was observed for hSULT1B1 in the presence of 1-OH-MC. Thus, a higher affinity of 1-OH-MC to hSULTB1 compared to orthologous enzymes may explain its increased bioactivation by the human enzyme. However, the species-dependent differences in inhibition (a parameter reflecting affinity) were not as dramatic as with the SULT1A1 enzymes.
Discussion
We demonstrated in this study that two major metabolites of MC can be activated to potent mutagens by the action of SULTs. In the first part of this study, we explored the role of individual human SULT forms in this activation. 1-and 2-OH-MC were activated with high selectivity by a single human SULT form, and this form was different for the isomeric MC metabolites tested. This situation contrasts to that observed with the positive control used, 1-HMP, which was activated by all SULT forms used. These differences may be rationalised on the basis of the mechanism of the enzyme, which involves a direct transfer of the sulpho group from the donor substrate (PAPS) to a nucleophilic group of the acceptor substrate in a deep pocket in the enzyme protein. Substrate and co-substrate enter this pocket (representing a channel) from two different openings (32, 33) . The primary -OH group of 1-HMP has much less steric constraints than the secondary -OH groups of 1-and 2-OH-MC, which are attached to a rigid cyclopenta ring. Therefore, its chance is better to reach an appropriate position for transfer of the sulpho group. On other hand, a substrate with a rigid structure will be favoured in the rare case when it perfectly fits the active centre of the enzyme, as may be the case for 1-OH-MC and human SULT1B1 as well as for 2-OH-MC and human SULT1A1.
In the second part of this study, we explored the capacity of orthologous SULT1A1 and SULT1B1 forms from human and laboratory animals to activate 1-and 2-OH-MC. Again, we observed high selectivity. This selectivity was extreme for the activation of 2-OH-MC by SULT1A1 enzymes. Mouse and rat SULT1A1 did not activate this compound, and the mutagenic activity in the presence of the dog enzyme remained low, only 0.15% of that observed with the human enzyme, although all SULT1A1 enzymes activated 1-HMP and conjugated acetaminophen efficiently (with rather similar results for the canine, mouse and human enzymes). hSULT1A1 did not only differ from its orthologues by the activation of 1-OH-MC, but also by an exceptionally strong inhibition of its acetaminophen sulphation activity in the presence of 1-OH-MC (and 2-OH-MC), demonstrating strong differences in affinity. It may be mentioned that the SULT1A subfamily substantially differs between species. This subfamily comprises only one gene in all investigated non-primate vertebrate species (including mouse, rat and dog), but four genes in humans (18) . Human SULT1A3 and SULT1A4 (identical on the protein level) are specialised for endogenous substrates, dopamine and other catecholamines, whereas human SULT1A1 has adopted a particularly broad function in xenobiotic metabolism. Human SULT1A2 is similar to SULT1A1, but generally expressed at lower levels. It is possible that the efficient activation of 2-OH-MC by human SULT1A1, but not by SULT1A1 enzymes from laboratory species, is associated with this evolution.
Pronounced species-dependent selectivity was also observed for the activation of 1-OH-MC by the SULT1B1 enzymes. The mutagenic activity mediated by the human enzyme exceeded that achieved with the other SULT1B1 forms by a factor of 24-300. A minor part of this difference may be due to differences in expression levels. However, it is obvious that the orthologous SULT1B1 enzymes differed in their substrate specificity. Thus, the mouse and rat SULT1B1 enzymes activated 2-OH-MC. They activated this isomer even better than 1-OH-MC by a factor of 2 based on the observed mutagenicity. In contrast, human SULT1B1 only activated 1-OH-MC, but not 2-OH-MC. Taking into account the limit of detection, its preference for 1-OH-MC reached a factor of at least 2400.
Most carcinogenicity studies on MC were conducted in mice and rats, and it appears that all carcinogenicity studies with individual MC metabolites, including 1-and 2-OH-MC, were performed in mice. Mouse SULT1B1 activated both isomers, although this activation was moderate compared to that observed with the most appropriate human SULTs. However, we have studied only two mouse SULT forms. It is possible that the mouse has additional forms with high sulphation activity toward 1-or 2-OH-MC.
The levels of SULTs expressed in recombinant Salmonella strains are higher than those found in human tissues (16, 34, 35) . In this context, it is mentionable that we used two strains expressing hSULT1A1 protein at varying levels. The mutagenic activity of 2-OH-MC was only increased 1.3-fold in the strain with the elevated expression level TA1538-hSULT1A1*1Y (with SULT1A1 contributing nearly 7% of the cytosolic protein) compared to the original strain (1% of the cytosolic protein), indicating that the enzyme level was not critical in this range. SULT1A1 levels of up to 0.49% have been reported in the cytosolic fraction of human liver samples (35); they certainly would be sufficient to activate 2-OH-MC, unlike other enzymes (e.g. uridine 5′-diphospho-glucuronosyltransferases) sequestered the substrate. The latter is not likely due to the very high affinity of SULT1A1 for 2-OH-MC, as demonstrated by the inhibition experiments.
It may be speculated that humans are even more sensitive to the carcinogenicity of MC than are mice and rats due to the efficient activation of 1-OH-MC by human SULT1B1 and of 2-OH-MC by human SULT1A1. However, this hypothesis remains academic, as no significant human exposure to MC is known.
1-OH-MC, activated by SULT1B1 enzymes, was not only mutagenic but also exhibited strong cytotoxicity. High cytotoxicity of a genotoxicant might enhance potential carcinogenic effects by stimulating cell turnover. However, it might also hinder the detection of carcinogenic activity by limiting the dose level that can be tested. 1′-Hydroxymethyleugenol is another SULT-dependent mutagen showing marked cytotoxicity in recombinant Salmonella strains (36) . It is a potent hepatocarcinogen in mice (37) .
This study was conducted with racemic OH-MCs, as was also the case with all previous biotransformation and carcinogenicity studies on these compounds. However, the docking analyses suggest that there might be substantial differences in the interaction of the enantiomers with SULT enzymes. It appears that only the (S)-enantiomer of 2-OH-MC and the (R)-enantiomer of 1-OH-MC are good substrates for hSULT1A1 and hSULT1B1, respectively. Therefore, there is a need to separate and assign the enantiomers.
The selective activations observed in this study were formidable, but not without precedence. Thus, α-hydroxytamoxifen, a metabolite of tamoxifen, which is genotoxic and carcinogenic in rat liver, was activated to a mutagen by a rat hepatic SULT (now termed SULT2A3), (18) but not by any other rat or human SULT form tested (38) . Indeed, we have tested all known human SULT forms for activation of α-hydroxytamoxifen with a negative result (H. Schneider and H. Glatt, unpublished result). Moreover, we have detected more than 100 compounds that are activated to mutagens by human SULTs expressed in S.typhimurium. With only few exceptions (such as 1-HMP), efficient activation of each promutagen was only observed with one or two human SULT forms (13, 39) . Rendic and Guengerich (40) systematically analysed the existing literature on the metabolism of carcinogens by human enzymes. SULTs took rank two-only preceded by the cytochromes P450-regarding the number of carcinogens activated by a class of xenobiotic-metabolizing enzymes. It is possible that the role of SULTs is still underestimated for technical reasons. Thus, many reactive metabolites produced by cytochrome P450 (e.g. epoxides) are able to penetrate cell membranes, enabling the usage of external activation systems (such as liver S9) in in-vitro test systems. This approach is usually not possible with sulpho conjugates, as they are charged molecules. Indeed, we have demonstrated for several SULTdependent mutagens that activation within the target cell is required for a positive test result (39, 41) . The involvement of specific SULT forms (varying for different compounds) together with the need of its expression in the target cell considerably complicates the detection of SULT-dependent bioactivation reactions.
Another complication results from pronounced speciesdependent differences in the activation of chemicals by SULTs, including orthologous enzymes. In order to explore such differences, we have constructed a number of mouse modelswith knockout of endogenous SULTs (for SULT1A1 and SULT1D1) or transgenes (for human SULT1A1, SULT1A2 and SULT1B1) and combinations therefrom. Initial results indicate a strong impact of such manipulations on the levels and tissue distributions of DNA damage produced by various SULT-dependent genotoxicants (42) (and various manuscripts in preparation).
